Table 1

Demographic and baseline characteristics of patients enrolled in the IMPACT 2 study and of the observational patient cohort

IMPACT 2 dataset (total)
CharacteristicInfliximabPlaceboObservational dataset
Patients, N18099
8991
Age, years (mean±SD)46.8±12.251.7±14.1
47.2±13.246.5±11.3
Disease duration, years (mean±SD)7.8±7.37.8±6.3
7.9±6.77.8±7.9
Female, %41.038.4
31.049.0
Glucocorticoids, %Unknown15.2
UnknownUnknown
Skin involvement, % patients10048.5
100100
PASI (mean±SD)9.3±10.11.6±2.6
9.6±11.28.9±8.9
DIP involvement,* % patients22.241.4
22.522.0
  • * According to the classification of PsA by Wright and Moll.3

  • DIP, distal interphalangeal joint; IMPACT 2, Infliximab Multinational Psoriatic Arthritis Controlled Trial 2; PASI, psoriasis area and severity index.